Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus Epiduo® Forte Gel in Treatment of Acne Vulgaris

• Register: ClinicalTrials.gov
• Last refreshed on: 12 December 2020
• Main ID: NCT02651220
• Date of registration: 05/01/2016
• Prospective Registration: No
• Primary sponsor: Actavis Inc.
• Public title: Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus Epiduo® Forte Gel in Treatment of Acne Vulgaris
• Date of first enrolment: November 2015
• Target sample size: 1001
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT02651220
• Study type: Interventional
• Study design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
• Phase: Phase 3

Countries of recruitment

Belize, United States

Key inclusion & exclusion criteria

Inclusion Criteria:

1. Male or non-pregnant, non-lactating female, = 12 and = 40 years of age with a clinical
diagnosis of acne vulgaris.

2. Signed informed consent form that meets all criteria of current FDA regulations. For a
patient considered to be a minor in the state he/she lives and is enrolled, the
patient parent or legal guardian will be required to sign the consent form and the
patient will sign an IRB approved "assent to participate" form.

3. Females of child bearing potential must not be pregnant or lactating at Visit 1 (as
confirmed by a negative urine pregnancy test with a sensitivity of less than 25 mlU/mL
or equivalent units of human chorionic gonadotropin). Women of childbearing potential
must agree to the use of a reliable method of contraception (e.g., total abstinence,
IUD, a double-barrier method [such as condom plus diaphragm with spermicide], oral,
transdermal, injected or implanted non- or hormonal contraceptive), throughout the
study. If the female is using a hormonal contraceptive, the same product must be taken
for 3 months prior to Visit 1 and must agree not to replace with some other hormonal
contraceptives during the study. A sterile sexual partner is not considered an
adequate form of birth control.

All females will be considered to be of childbearing potential unless they:

- Are post-menopausal, defined as women who have been amenorrheic for at least 12
consecutive months, without other known or suspected primary cause.

- Have been sterilized surgically or who are otherwise proven sterile (i.e., total
hysterectomy, or bilateral oophorectomy) with surgery at least 4 weeks prior to
Screening. Tubal ligation will not be considered a surgically sterile method.

Female patients of childbearing potential are defined as:

- Females without prior hysterectomy, or who have had any evidence of menses in the
past 12 months.

- Females who have been amenorrhea for = 12 months, but the amenorrhea is possibly
due to other causes, including prior chemotherapy, anti-estrogens, or ovarian
suppression.

4. Have facial acne vulgaris with: = 20 inflammatory lesions (i.e., papules and pustules)
and = 25 non-inflammatory lesions (i.e., open and closed comedones) and = 2
nodulocystic lesions (i.e., nodules and cysts).

5. Have an Investigator's Global Assessment (IGA) score of 3 or 4 (see Appendix A).

6. Willing to comply with the study requirements and restrictions including refraining
from the use of all other topical acne medications or antibiotics during the 12 week
treatment period.

7. Patients who use make-up must have used the same brands/types for a minimum period of
14 days before study entry and must agree to not change brand/type or frequency of use
throughout the study.

Exclusion Criteria:

1. Patient has more than 2 facial nodular lesions; any nodules present will be documented
but not included in the inflammatory and non-inflammatory lesion count for analysis.

2. Patient has active cystic acne.

3. Patient has acne conglobata, acne fulminans, or acne vulgaris requiring systemic
treatment.

4. Patient has a skin condition that would interfere with the diagnosis or assessment of
acne vulgaris (e.g., on the face: rosacea, dermatitis, psoriasis, squamous cell
carcinoma, eczema, acneform eruptions caused by medications, steroid acne, steroid
folliculitis, bacterial folliculitis).

5. Patients with excessive facial hair such as beards, sideburns, moustaches, etc. that
would interfere with the diagnosis or assessment of acne.

6. Patients with tattoos or excessive facial scarring that, in the Investigator's
opinion, may interfere with the evaluation of the patient's acne.

7. Patients with active facial sunburn, peeling from sunburn, or patients that will be
exposed to excessive sunlight during the study.

8. Females who are pregnant, lactating or likely to become pregnant during the study.

9. History of allergy or hypersensitivity to adapalene, retinoids, benzoyl peroxide or
history of any drug hypersensitivity or intolerance that, in the Investigator's
opinion, would compromise the safety of the patient or the study.

10. Significant history or current evidence of chronic infectious disease, system
disorder, organ disorder or other medical condition that, in the Investigator's
opinion, would place the study participant at undue risk by participation.

11. Use of the following on the face within 1 month before Screening/Baseline:

- Cryodestruction or chemodestruction

- Dermabrasion

- Photodynamic therapy

- Acne surgery

- Intralesional steroids

- X-ray therapy

12. Use of the following within 1 month before Screening/Baseline:

- Spironolactone

- Systemic steroids

- Systemic antibiotics

- Systemic anti-inflammatory agents (the use of acetylsalicylic acid for
prophylactic use up to 325 mg/day is allowed, provided that the patient is on a
stable dose and the regimen will remain constant throughout the study).
Acetaminophen will be allowed during the study with a maximum dose of 1g (i.e.,
1000 mg) twice daily and for a maximum of 3 consecutive days (its use is not
allowed within 1 week of each visit).

- Systemic treatment for acne vulgaris (other than oral retinoids that require a 6
month washout), including anti-androgens.

13. Use of oral isotretinoin (Accutane®) or oral retinoids within 6 months, or therapeutic
vitamin A supplements greater than 10,000 units/day (multivitamins are allowed).

14. Use of the following on the face within 2 weeks before Screening/Baseline:

- Topical steroids

- Topical retinoids

- Topical zinc

- Topical anti-inflammatory agents (including salicylic acid)

- Topical antibiotics (including antibacterials)

- Benzoyl peroxide

- Any other topical over-the-counter preparations for acne treatment

15. Use of the following on the face within 1 week before Screening/Baseline:

- Phototherapy devices for acne (e.g., ClearLightTM)

- Medicated cleansers including adhesive cleansing strips

- Cosmetic procedures (i.e., facials, peeling, comedone extraction) and
alpha-hydroxy/glycolic acid

16. Receipt of any drug as pa


Age minimum: 12 Years
Age maximum: 40 Years
Gender: All

Health Condition(s) or Problem(s) studied

Acne

Intervention(s)

Drug: Adapalene and Benzoyl Peroxide Gel

Drug: placebo gel

Drug: Epiduo® Forte Gel

Primary Outcome(s)

Percent Change From Baseline to Week 12 in the Number of Inflamed Lesions. [Time Frame: 12 weeks]

Percent Change From Baseline to Week 12 in the Number of Non-inflamed Lesions. [Time Frame: 12 weeks]

Secondary Outcome(s)

Percentage of Patients With a Clinical Response of "Clinical Success" Using the Investigator's Global Assessment (IGA) at Week 12 [Time Frame: 12 weeks]

Secondary ID(s)

71491705

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Results

• Results available: Yes
• Date Posted: 23/06/2020
• URL: https://clinicaltrials.gov/ct2/show/results/NCT02651220